Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2003 Feb 18;100(4):1891-5.
doi: 10.1073/pnas.0437788100. Epub 2003 Feb 4.

Pretarget radiotherapy with an anti-CD25 antibody-streptavidin fusion protein was effective in therapy of leukemia/lymphoma xenografts

Meili Zhang  1 , Zhuo Zhang, Kayhan Garmestani, Jody Schultz, Donald B Axworthy, Carolyn K Goldman, Martin W Brechbiel, Jorge A Carrasquillo, Thomas A Waldmann
Affiliations

Pretarget radiotherapy with an anti-CD25 antibody-streptavidin fusion protein was effective in therapy of leukemia/lymphoma xenografts

Meili Zhang et al. Proc Natl Acad Sci U S A. .

Abstract

Although radioimmunotherapy with radiolabeled intact monoclonal antibodies has demonstrated efficacy in the treatment of lymphoma, it provides low tumor-to-normal-tissue radionuclide target ratios and unwanted prolonged radiation exposure to the bone marrow. To overcome these obstacles, the administration of the radionuclide was separated from that of the antibody by using an anti-IL-2 receptor alpha antibody single chain Fv-streptavidin fusion protein, followed by radiolabeled biotin to treat lymphoma or leukemia xenografted mice. This Pretarget approach provided extremely rapid and effective tumor targeting, permitting the use of short-lived alpha-emitting radionuclides. With the beta-emitter (90)Y, all of the 10 lymphoma-xenografted mice were cured. With the alpha-emitter (213)Bi, significant efficacy was obtained in treating leukemic mice, and, furthermore, when combined with immunotherapy, 7 of 10 leukemic mice were cured. Thus, Pretarget radioimmunotherapy is very promising and could represent the next generation in the treatment of lymphoma and leukemia.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Biodistributions of radioactivity in SUDHL-1 lymphoma-bearing mice. (A) Pretarget approach. (B) Directly labeled HAT. Bars represent the mean ± SD of the percentage of ID per gram of tissue (%ID/g).
Figure 2
Figure 2
Therapy of SUDHL-1 lymphoma-bearing mice with 90Y-DOTA-biotin in the Pretarget approach. Tumor volume (A) and Kaplan–Meier survival (B) plots are shown. nrPRIT, no-radionuclide PRIT.
Figure 3
Figure 3
Kaplan–Meier survival plot of MET-1 leukemia-bearing SCID/NOD mice with 213Bi-DOTA-biotin in the Pretarget approach.
See this image and copyright information in PMC

References

    1. Knox S J, Goris M L, Trisler K, Negrin R, Davis T, Liles T M, Grillo-Lopez A, Chinn P, Varns C, Ning S C, et al. Clin Cancer Res. 1996;2:457–470. - PubMed
    1. Waldmann T A, White J D, Carrasquillo J A, Reynolds J C, Paik C H, Gansow O A, Brechbiel M W, Jaffe E S, Fleisher T A, Goldman C K. Blood. 1995;86:4063–4075. - PubMed
    1. Kaminski M S, Zasadny K R, Francis I R, Milik A W, Ross C W, Moon S D, Crawford S M, Burgess J M, Petry N A, Butchko G M, et al. N Engl J Med. 1993;329:459–465. - PubMed
    1. Press O W, Eary J F, Appelbaum F R, Martin P J, Badger C C, Nelp W B, Glenn S, Butchko G, Fisher D, Porter B, et al. N Engl J Med. 1993;329:1219–1224. - PubMed
    1. Knox S J. Cancer Res. 1995;55:5832s–5836s. - PubMed

Publication types